ICU Medical, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited fourth-quarter results. Financial statements are audited, and the auditor expressed an unqualified opinion.
Business context
ICU Medical develops and sells medical devices for infusion therapy, critical care and oncology. In 2016, infusion therapy represented 72% of revenue, critical care 14% and oncology 14%. The company reported one operating segment for financial reporting.
Financial results
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Total revenue | $379.4 million | $341.7 million | +11% |
| Gross profit / margin | $201.4 million / 53.1% | $180.8 million / 52.9% | Margin +0.2 percentage points |
| Operating income / margin | $82.9 million / 21.9% | $68.6 million / 20.1% | +21% |
| Net income | $63.1 million | $45.0 million | +40% |
| Diluted EPS | $3.66 | $2.73 | +34% |
| Cash from operations | $89.9 million | $64.2 million | +$25.7 million |
Fourth quarter: Revenue was $95.7 million, gross profit $50.8 million, net income $9.5 million and diluted EPS $0.54. In fourth-quarter 2015, the corresponding figures were $90.4 million, $48.3 million, $5.5 million and $0.33.
Revenue by product group was $272.6 million in infusion therapy (+11%), $53.6 million in critical care (-1%) and $52.3 million in oncology (+26%). Direct infusion and oncology sales grew, while critical care revenue declined amid temporary production constraints earlier in the year. Gross margin improved slightly, primarily due to favorable foreign exchange on Mexican operating costs and product mix, partly offset by manufacturing constraints.
Balance sheet, liquidity and cash flow
- At December 31, 2016, cash and investment securities totaled $445.1 million, up from $377.4 million a year earlier; all investment securities had been liquidated by year-end to fund the planned HIS acquisition. Working capital was $528.6 million.
- Total assets were $704.7 million and stockholders’ equity was $660.2 million. Year-end current liabilities were $40.5 million. The filing reports no material conventional debt at year-end; long-term liabilities were $1.1 million.
- Operating cash flow was $89.9 million; capital expenditures were $23.4 million. The increase in operating cash flow versus 2015 reflected higher earnings and smaller working-capital cash outflows.
- After the February 2017 HIS acquisition, the company reported approximately $270 million of cash. The transaction included a three-year, interest-only $75 million seller note, due February 3, 2020, bearing interest at LIBOR plus 2.25% for the first year and 2.5% thereafter.
Material changes and unusual items
- Pfizer accounted for 30% of 2016 revenue, down from 36% in each of 2015 and 2014, and 23% of year-end accounts receivable. ICU Medical acquired Pfizer’s Hospira Infusion Systems (HIS) business on February 3, 2017, intending to reduce customer concentration and expand its infusion portfolio and distribution reach.
- HIS consideration included $275 million in cash, a $75 million seller note and 3.2 million newly issued shares. Pfizer may receive up to an additional $225 million based on combined-company performance through 2019. The acquisition’s purchase accounting was incomplete when the 10-K was filed.
- 2016 restructuring and strategic transaction expenses totaled $15.3 million, including $14.3 million of transaction costs, primarily related to HIS and other acquisitions. The company also recorded a $0.7 million impairment loss on the sale of its Slovakian facility and a $1.5 million bargain purchase gain on the Tangent acquisition.
- The effective tax rate was 25.9%, versus 35.5% in 2015. Adoption of stock-compensation accounting guidance produced a $7.6 million discrete tax benefit in 2016, materially contributing to the lower rate and higher net income.
Outlook, risks and contingencies
- Management expected 2017 legacy-business capital expenditures of approximately $18–$20 million and said existing cash and expected operating cash flows should fund operations and the HIS acquisition for the next 12 months. This is not earnings guidance; the filing provides no specific revenue or EPS forecast.
- The company planned a post-acquisition workforce restructuring, estimating charges of $3.8–$4.2 million in the first half of 2017, mostly payable by the end of the third quarter.
- Management identified HIS integration, transitional reliance on Pfizer services, retention of customers and employees, and achievement of anticipated synergies as significant risks. Pfizer’s contingent earnout could also increase transaction costs.
- Other risks include reliance on Mexico manufacturing and potential labor or cross-border disruptions; single- or limited-source suppliers; dependence on Clave products; competition and pricing pressure; regulatory and reimbursement changes; product liability and recalls; patent disputes; foreign-exchange exposure (not hedged); and customer/distributor credit risk. The company reported effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Whether HIS integration delivers the expected growth, distribution efficiencies and lower customer concentration, and whether temporary Pfizer services can be transitioned successfully.
- The acquired HIS business’s finalized purchase accounting, pro forma results, operating performance and any working-capital or other purchase-price adjustments.
- Whether combined adjusted EBITDA reaches the earnout thresholds, potentially triggering up to $225 million of additional cash consideration.
- Post-acquisition cash generation, debt-service capacity and liquidity after the $75 million seller note and planned capital spending.
- Whether the $7.6 million tax benefit and other transaction or restructuring items affect comparisons with future recurring earnings.